Our Mission:
Pharmacyclics is committed to improving the lives of patients with cancer and other serious diseases through research, development and commercialization of novel small-molecule drugs. We have focused our development on innovative therapies that selectively target diseased cells through unique molecular pathways.
Pharmacyclics is a pharmaceutical company developing innovative treatments for cancer and immune-mediated diseases. The company is working on a range of clinical and laboratory programs and is pursuing the development of novel drugs aimed at specific disease pathways.
The company's lead compound, motexafin gadolinium (MGd), is a rationally designed small molecule, the first in a class of drugs called texaphyrins that concentrate in diseased tissue and disrupt cellular metabolism. MGd is in late-stage development for brain metastases from lung cancer.
The company also has a broad pipeline of product opportunities in either Phase 1, Phase 2 or preclinical stages of development for cancer and autoimmune diseases.
- A histone deacetylase (HDAC) inhibitor, which inhibits tumor growth by interfering with cancer cell DNA transcription
- A Factor VIIa inhibitor to inhibit tumor growth and angiogenesis or
- Tyrosine kinase inhibitors to prevent B-cell maturation, undergoing investigation for the treatment of lymphomas and autoimmune disorders.